4.135
3.10%
0.135
Cabaletta Bio Inc stock is traded at $4.135, with a volume of 217.97K.
It is up +3.10% in the last 24 hours and down -3.19% over the past month.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases.
See More
Previous Close:
$4.00
Open:
$3.99
24h Volume:
217.97K
Relative Volume:
0.21
Market Cap:
$198.57M
Revenue:
-
Net Income/Loss:
$-67.68M
P/E Ratio:
-2.3902
EPS:
-1.73
Net Cash Flow:
$-54.24M
1W Performance:
-1.81%
1M Performance:
-3.19%
6M Performance:
-66.72%
1Y Performance:
-74.23%
Cabaletta Bio Inc Stock (CABA) Company Profile
Name
Cabaletta Bio Inc
Sector
Industry
Phone
(267) 759-3100
Address
2929 ARCH STREET, PHILADELPHIA, PA
Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Sep-05-23 | Initiated | Citigroup | Buy |
Jul-18-23 | Initiated | Guggenheim | Buy |
Jan-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Aug-30-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Dec-08-21 | Initiated | Wells Fargo | Overweight |
Oct-19-21 | Resumed | Morgan Stanley | Overweight |
Jun-30-21 | Initiated | Mizuho | Buy |
Jan-08-21 | Initiated | Chardan Capital Markets | Buy |
Oct-13-20 | Initiated | H.C. Wainwright | Buy |
Nov-19-19 | Initiated | Cowen | Outperform |
Nov-19-19 | Initiated | Evercore ISI | Outperform |
Nov-19-19 | Initiated | Morgan Stanley | Overweight |
View All
Cabaletta Bio Inc Stock (CABA) Latest News
Vanguard Group Inc's Strategic Acquisition of Cabaletta Bio Inc Shares - GuruFocus.com
Cabaletta Bio, Inc. (NASDAQ:CABA) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
UBS Initiates Coverage of Cabaletta Bio (CABA) with Buy Recommendation - MSN
We're Not Very Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Rate - Yahoo Finance
Cabaletta Bio, Inc. (NASDAQ:CABA) Short Interest Down 28.9% in October - MarketBeat
Undercovered Dozen: CorMedix, Cabaletta, Skyx Platforms, Dynex Capital + - Seeking Alpha
Cabaletta: Biotech With Large Potential, Interesting Bottom Pattern, Plenty Of Cash - Seeking Alpha
State Street Corp's Strategic Reduction in Cabaletta Bio Inc Holdings - Yahoo Finance
State Street Corp's Strategic Reduction in Cabaletta Bio Inc Hol - GuruFocus.com
Short Interest in Cabaletta Bio, Inc. (NASDAQ:CABA) Drops By 16.7% - MarketBeat
Trading Day Review: Cabaletta Bio Inc (CABA) Gains Momentum, Closing at 4.21 - The Dwinnex
Millennium Management LLC Grows Stock Position in Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat
Kyverna, Cabaletta started at buys by UBS on CAR T therapy potential - MSN
UBS sees significant upside for Cabaletta Bio despite recent share decline - Investing.com India
Kyverna, Cabaletta started at buys by UBS on CAR T therapy potential (NASDAQ:KYTX) - Seeking Alpha
Healthy Upside Potential: Cabaletta Bio Inc (CABA) - SETE News
UBS sees significant upside for Cabaletta Bio despite recent share decline By Investing.com - Investing.com South Africa
Cabaletta Bio (NASDAQ:CABA) Now Covered by Analysts at UBS Group - MarketBeat
A Guide To The Risks Of Investing In Cabaletta Bio Inc (CABA) - Knox Daily
Cabaletta Bio Inc (CABA) stock analysis: A comprehensive overview - US Post News
Cabaletta Bio Outlines Future Trials and Development Strategy - TipRanks
Squarepoint Ops LLC Has $2.36 Million Stake in Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat
Marshall Wace LLP Grows Stake in Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
Get in on Cabaletta Bio Inc’s (CABA) buy-in window today! - SETE News
Should investors be concerned about Cabaletta Bio Inc (CABA)? - US Post News
Cabaletta Bio Inc: Buy, Hold, or Sell? Analysts Weigh In Amid Market Challenges - The InvestChronicle
Cabaletta Bio secures lease terms through August 2026 - Investing.com India
Cabaletta Bio secures lease terms through August 2026 By Investing.com - Investing.com South Africa
Ratios Reveal: Breaking Down Cabaletta Bio Inc (CABA)’s Financial Health - The Dwinnex
Perceptive Advisors LLC Cuts Position in Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat
Lynx1 Capital Management LP Lowers Stock Position in Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
Wall Street SWOT: Cabaletta Bio stock pioneers CAR-T in immunology amid challenges - Investing.com
Lynx1 Capital Management LP Has $3.68 Million Stock Position in Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat
Cabaletta Bio to Present Key Findings on CABA-201 at ACR Convergence 2024 - MSN
Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024 - ForexTV.com
Deerfield Management Company L.P. Series C Reduces Stock Holdings in Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat
Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR - EIN News
Cabaletta Bio Inc (CABA) Performance and Fundamentals Dashboard tells a completely different story - SETE News
Cabaletta Bio Inc Inc. (CABA) Price Performance: The Role of Share Buybacks and Stock Splits - The InvestChronicle
Balance Sheet Breakdown: Cabaletta Bio Inc (CABA)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Technical analysis of Cabaletta Bio Inc (CABA) stock chart patterns - US Post News
Nothing is Better Than Cabaletta Bio Inc (CABA) stock at the moment - SETE News
Cabaletta Bio Inc: Navigating Market Fluctuations with a 204.68M Market Cap - The InvestChronicle
Cabaletta Bio, Inc. (NASDAQ:CABA) Shares Purchased by E Fund Management Co. Ltd. - MarketBeat
Cabaletta Bio shares maintain Buy rating from H.C. Wainwright - Investing.com India
Cabaletta Bio (NASDAQ:CABA) Stock Rating Reaffirmed by HC Wainwright - MarketBeat
Cabaletta Bio shares maintain Buy rating from H.C. Wainwright By Investing.com - Investing.com UK
Financial Fitness Check: Examining Cabaletta Bio Inc (CABA)’s Key Ratios - The Dwinnex
Was anything positive for Cabaletta Bio Inc (CABA) stock last session? - US Post News
Cabaletta Bio, Inc. (NASDAQ:CABA) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
TD Asset Management Inc Raises Holdings in Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
Cabaletta Bio Inc Stock (CABA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cabaletta Bio Inc Stock (CABA) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Binder Gwendolyn | See Remarks |
Jan 19 '24 |
Sale |
19.59 |
11,000 |
215,439 |
20,000 |
Binder Gwendolyn | See Remarks |
Dec 19 '23 |
Option Exercise |
1.01 |
11,000 |
11,110 |
31,000 |
Binder Gwendolyn | See Remarks |
Dec 19 '23 |
Sale |
21.89 |
11,000 |
240,789 |
20,000 |
Binder Gwendolyn | See Remarks |
Nov 20 '23 |
Option Exercise |
1.01 |
11,000 |
11,110 |
31,000 |
Binder Gwendolyn | See Remarks |
Nov 20 '23 |
Sale |
17.82 |
11,000 |
196,014 |
20,000 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):